**Core Concept:**
Carbimazole is a medication used to treat hyperthyroidism, specifically in cases of toxic multinucleated goiter and Graves' disease. It is a prodrug converted to its active form, methimazole, in the liver, which inhibits thyroid hormone synthesis by inhibiting the enzyme thymidine kinase. The plasma half-life of carbimazole determines how long it remains in the bloodstream before being eliminated from the body.

**Why the Correct Answer is Right:**
The correct answer is D (4 days). The plasma half-life of carbimazole is around 4 days due to its conversion into methimazole and subsequent binding to plasma proteins. This binding retards the drug's elimination from the body, resulting in a longer half-life. Methimazole is then eliminated via the kidneys, contributing to the prolonged half-life of carbimazole.

**Why Each Wrong Option is Incorrect:**
A (0.5 days): This is too short a half-life for carbimazole, suggesting rapid elimination which is not the case.
B (20 days): This is also too long, indicating a slower elimination rate than the actual half-life.
C (7 days): This is an intermediate value, but the correct answer (4 days) is more precise and accurate.

**Clinical Pearl / High-Yield Fact:**
Understanding the plasma half-life of medications like carbimazole is crucial for safe and effective dosing. A longer half-life means the drug will stay in the body for a longer period, potentially leading to toxicity if the dose is not adjusted accordingly. Conversely, a shorter half-life indicates a need for more frequent administration to maintain therapeutic levels. In the case of carbimazole, its longer half-life allows for once-daily administration, simplifying treatment and reducing patient compliance issues.